Anas Younes

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
    Anas Younes
    Memorial Sloan Kettering Cancer Center, New York, NY, USA Electronic address
    Lancet Oncol 17:1283-94. 2016
  2. pmc Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial
    Anas Younes
    Memorial Sloan Kettering Cancer Center, New York, NY, USA Electronic address
    Lancet Oncol 17:622-31. 2016
  3. doi request reprint Promising Novel Agents for Aggressive B-Cell Lymphoma
    Anas Younes
    Lymphoma Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA Electronic address
    Hematol Oncol Clin North Am 30:1229-1237. 2016
  4. pmc Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy
    Antonino Carbone
    Department of Pathology, Centro di Riferimento Oncologico CRO Aviano, Istituto Nazionale Tumori, IRCCS, Via F Gallini 2, 33081, Aviano, Italy
    Ann Hematol 93:1263-77. 2014
  5. doi request reprint Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study
    Anas Younes
    Memorial Sloan Kettering Cancer Center, New York, NY, USA Electronic address
    Lancet Oncol 15:1019-26. 2014
  6. doi request reprint Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study
    Anas Younes
    University of Texas MD Anderson Cancer Center, Houston, TX, USA Electronic address
    Lancet Oncol 14:1348-56. 2013
  7. doi request reprint Brentuximab vedotin for the treatment of patients with Hodgkin lymphoma
    Anas Younes
    Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA Electronic address
    Hematol Oncol Clin North Am 28:27-32. 2014
  8. pmc Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma
    Anas Younes
    Departments of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 119:4123-8. 2012
  9. pmc Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma
    Yasuhiro Oki
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 163:611-20. 2013
  10. doi request reprint Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma
    Jorge E Romaguera
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 150:200-8. 2010

Detail Information

Publications45

  1. pmc Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
    Anas Younes
    Memorial Sloan Kettering Cancer Center, New York, NY, USA Electronic address
    Lancet Oncol 17:1283-94. 2016
    ..We aimed to assess the clinical benefit and safety of nivolumab monotherapy in patients with classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin...
  2. pmc Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial
    Anas Younes
    Memorial Sloan Kettering Cancer Center, New York, NY, USA Electronic address
    Lancet Oncol 17:622-31. 2016
    ..We aimed to assess overall safety and preliminary activity in this dose-escalation study of CUDC-907 monotherapy in patients with relapsed or refractory lymphoma and multiple myeloma...
  3. doi request reprint Promising Novel Agents for Aggressive B-Cell Lymphoma
    Anas Younes
    Lymphoma Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA Electronic address
    Hematol Oncol Clin North Am 30:1229-1237. 2016
    ..Since then, no other agents have been approved for the treatment of DLBCL. This article reviews recent data on the most promising agents in development for the treatment of DLBCL...
  4. pmc Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy
    Antonino Carbone
    Department of Pathology, Centro di Riferimento Oncologico CRO Aviano, Istituto Nazionale Tumori, IRCCS, Via F Gallini 2, 33081, Aviano, Italy
    Ann Hematol 93:1263-77. 2014
    ..Immunohistochemistry for detecting the expression of these biomarkers is a practical technique that could provide a rational for clinical trial design...
  5. doi request reprint Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study
    Anas Younes
    Memorial Sloan Kettering Cancer Center, New York, NY, USA Electronic address
    Lancet Oncol 15:1019-26. 2014
    ..We investigated the safety and efficacy of ibrutinib in combination with R-CHOP for patients with previously untreated CD20-positive B-cell non-Hodgkin lymphoma...
  6. doi request reprint Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study
    Anas Younes
    University of Texas MD Anderson Cancer Center, Houston, TX, USA Electronic address
    Lancet Oncol 14:1348-56. 2013
    ..We aimed to assess the safety and early clinical efficacy of this drug as first-line treatment in combination with standard or modified-standard treatment in patients with previously untreated Hodgkin's lymphoma...
  7. doi request reprint Brentuximab vedotin for the treatment of patients with Hodgkin lymphoma
    Anas Younes
    Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA Electronic address
    Hematol Oncol Clin North Am 28:27-32. 2014
    ..This review summarizes the current and future directions of incorporating brentuximab vedotin in the management of patients with HL...
  8. pmc Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma
    Anas Younes
    Departments of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 119:4123-8. 2012
    ..Our results demonstrate that the addition of rituximab to ABVD is safe and has a promising clinical activity in patients with advanced-stage cHL. These data are currently being confirmed in a multicenter randomized trial...
  9. pmc Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma
    Yasuhiro Oki
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 163:611-20. 2013
    ..In conclusion, R-HCVAD/R-MA is associated with excellent outcome in patients ≤45 years old. However, in patients >45 years old, R-HCVAD/R-MA is associated with unacceptable mortality rates. ..
  10. doi request reprint Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma
    Jorge E Romaguera
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 150:200-8. 2010
    ..We conclude that intense chemoimmunotherapy without stem cell transplantation is effective for untreated aggressive MCL...
  11. pmc The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines
    Manuela Lemoine
    Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 119:4017-25. 2012
    ....
  12. pmc Detection of ABCC1 expression in classical Hodgkin lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols
    Wesley Greaves
    Department of Hematopathology, Unit 72, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
    J Hematol Oncol 5:47. 2012
    ..ATP-binding cassette (ABC) transporters confer multidrug resistance in various cancers and ABCC1 overexpression has been shown to contribute to drug resistance in the CHL cell line, KMH2...
  13. pmc Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center
    Dai Chihara
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 172:80-8. 2016
    ....
  14. pmc Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
    Jason R Westin
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 167:177-84. 2014
    ..Given the declining therapeutic outcomes of salvage PBC in the rituximab era, further evaluation of TTR is warranted. ..
  15. pmc High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma
    Meghan Karuturi
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 19:991-4. 2013
    ..Our data suggest that high-dose chemotherapy and autologous transplantation should be considered as an option for patients with relapsed NLPHL...
  16. pmc Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas
    Felipe Samaniego
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 169:814-23. 2015
    ..This is the first report demonstrating the effectiveness of pentostatin, cyclophosphamide and rituximab in patients with previously untreated iNHLs, including those over 60 years of age. ..
  17. pmc Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma
    Yasuhiro Oki
    Department of Lymphoma Myeloma, The University of Texas, M D Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 171:463-70. 2015
    ..Our data demonstrate that MK2206 has a favourable safety profile with a modest activity in patients with relapsed Hodgkin lymphoma. The future studies should explore mechanism-based combinations (clinicaltrials.gov NCT01258998). ..
  18. pmc The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma
    Yasuhiro Oki
    Department of Lymphoma Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 165:112-6. 2014
    ..44·4%(P = 0·155), respectively. The outcome after positive PET2 was better than previously reported. The results from non-randomized studies of PET2-guided therapy would be valuable with careful interpretation. ..
  19. doi request reprint Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma
    Dai Chihara
    Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 171:509-16. 2015
    ..This study was registered at www.clinicaltrials.gov as #NCT00290433. ..
  20. pmc Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial
    Yasuhiro Oki
    Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX Electronic address
    Clin Lymphoma Myeloma Leuk 15:152-8. 2015
    ....
  21. pmc Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma
    Anna Alperovich
    From the Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY
    Cancer J 22:23-6. 2016
    ..In this review article, we discuss the current and ongoing development of brentuximab vedotin in patients with relapsed and newly diagnosed HL. ..
  22. pmc Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach
    Yasuhiro Oki
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 169:689-93. 2015
    ..This data demonstrates the feasibility of detecting circulating tumour-specific sequences, creating an unprecedented opportunity to optimize the future treatment and monitoring strategies for patients with CHL. ..
  23. ncbi request reprint The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9
    Georgios V Georgakis
    Department of Lymphoma and Myeloma, The University of Texas, MD Anderson Cancer Center MDACC, Houston, TX, USA
    Br J Haematol 135:68-71. 2006
    ..These data suggest that 17-AAG may have a potential therapeutic value in patients with MCL...
  24. ncbi request reprint Antibody-drug conjugate technology development for hematologic disorders
    Neil H Bander
    Weill Medical College Cornell University, New York Presbyterian Hospital and Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Adv Hematol Oncol 10:1-16. 2012
    ..Other ADCs in clinical trials for hematologic disorders include inotuzumab ozogamicin, SAR3419, and gemtuzumab ozogamicin...
  25. pmc HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma
    Daniela Buglio
    Departments of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 117:2910-7. 2011
    ..These results demonstrate for the first time that HDAC11 plays an essential role in regulating OX40L expression. Pharmacologic inhibition of HDAC11 may produce a favorable antitumor immune response in patients with HL...
  26. ncbi request reprint Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma
    John P Leonard
    Center for Lymphoma and Myeloma, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY 10021, USA
    Clin Adv Hematol Oncol 6:437-45. 2008
    ..This review focuses on the development of novel therapies for rituximab-pretreated, relapsed or refractory indolent NHL...
  27. pmc Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma
    Beatriz Sánchez-Espiridión
    Department of Pathology, M D Anderson Cancer Center, Houston, TX, USA
    Haematologica 97:1080-4. 2012
    ..In conclusion, individual tumor associated macrophage markers cannot be used to predict outcome before technical standardization and prospective validation in independent series of patients with comparable stages and treatments...
  28. doi request reprint PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study
    Alison J Moskowitz
    Memorial Sloan Kettering Cancer Center, New York, NY, USA Electronic address
    Lancet Oncol 16:284-92. 2015
    ..In this study, we assessed the feasibility and activity of PET-adapted salvage therapy with brentuximab vedotin, followed by augmented ifosfamide, carboplatin, and etoposide (ICE)...
  29. doi request reprint Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma
    Barbara Pro
    Department of Lymphoma Myeloma, MD Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 143:355-60. 2008
    ..In conclusion, oblimersen sodium can be safely combined with rituximab. The combination appears to be most beneficial in patients with indolent NHL and warrants further investigation in a large randomized trial...
  30. pmc The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism
    Daniela Buglio
    M D Anderson Cancer Center, Department of Lymphoma Myeloma, Houston, University of Texas, TX, USA
    Br J Haematol 151:387-96. 2010
    ..Thus, our results demonstrate that MGCD0103 may synergize with proteasome inhibitors by HDAC6-independent mechanisms, providing mechanistic rationale for exploring this potentially less toxic combination for the treatment of lymphoma...
  31. pmc Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma
    Michelle Fanale
    University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 164:258-65. 2014
    ..Lucatumumab demonstrates modest activity in relapsed/refractory patients with advanced lymphoma, suggesting that targeting of CD40 warrants further investigation. ..
  32. doi request reprint The landscape of new drugs in lymphoma
    Anas Younes
    Lymphoma Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Nat Rev Clin Oncol . 2016
    ..We also address new approaches for patient selection and for incorporating new end points into clinical trials...
  33. doi request reprint Novel therapy for Hodgkin lymphoma
    Connie Lee Batlevi
    1Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY
    Hematology Am Soc Hematol Educ Program 2013:394-9. 2013
    ..Brentuximab vedotin, which was approved in 2011, is already shifting the treatment paradigm of HL. Undoubtedly, other novel therapeutics in the pipeline will affect positively the landscape of treatment in HL. ..
  34. pmc Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor
    Yanis Boumber
    University of Texas M D Anderson Cancer Center, Division of Cancer Medicine, Houston, TX, USA
    Expert Opin Investig Drugs 20:823-9. 2011
    ..As single agents, HDACIs have clinical activity in lymphoma. In myeloid leukemias, combinations of DNA methylation inhibitors and HDACIs are promising. Other combinations are being studied in solid tumors...
  35. pmc Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Anita Kumar
    Memorial Sloan Kettering Cancer Center, New York, NY and
    Blood 128:1458-64. 2016
    ..This trial was registered at www.clinicaltrials.gov as #NCT01868451. ..
  36. doi request reprint Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations
    Catherine S Diefenbach
    NYU Perlmutter Cancer Center, New York, NY CSD BC Cancer Agency Centre for Lymphoid Cancer, Vancouver, BC, Canada JMC Wilmot Cancer Center and Division of Hematology Oncology, University of Rochester Medical Center, Rochester, NY JWF Department of Medicine, Weil Cornell University, New York, NY JPL Oncology Division, Department of Medicine, Washington University, St Louis, MO BSK, NLB Division of Cancer Treatment and Diagnosis RFL and Coordinating Center for Clinical Trials LB, Tufts Cancer Center and Division of Hematology Oncology, Tufts University School of Medicine, Boston, MA AME Stanford Cancer Institute, Stanford University Medical School, Stanford, CA RTH Division of Pediatric Hematology Oncology Stem Cell Transplant, Columbia University Medical Center, New York, NY KMK Department of Medicine, University of Arizona Cancer Center, Tucson, AZ DOP Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY AY Department of Radiology, Mount Sinai Hospital, New York, NY LK
    J Natl Cancer Inst 109:. 2017
    ..Finally, we suggest areas of unmet need in HL and elucidate promising therapeutic strategies to guide future HL clinical trials planning across the NCTN...
  37. doi request reprint Brentuximab vedotin in systemic T-cell lymphoma
    Yasuhiro Oki
    Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Expert Opin Biol Ther 12:623-32. 2012
    ..The efficacy of brentuximab vedotin in other CD30(+) lymphomas is currently being investigated...
  38. pmc Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma
    Patrizia Mondello
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Oncotarget . 2017
    ..Collectively, these data provide a mechanistic rationale for evaluating CUDC-907 for the treatment of patients with Myc and PI3K-dependent lymphomas...
  39. doi request reprint Novel agents in the treatment of Hodgkin lymphoma: Biological basis and clinical results
    Anas Younes
    Memorial Sloan Kettering Cancer Center, New York, NY
    Semin Hematol 53:186-9. 2016
    ..Multiple clinical trials are currently ongoing testing these agents in the relapsed and refractory setting but also in earlier phases of therapy often in combination with more standard treatment. ..
  40. doi request reprint Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma
    Eri Matsuki
    Lymphoma Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 330, New York, NY, 10065, USA
    Curr Treat Options Oncol 17:31. 2016
    ....
  41. pmc ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma
    Connie Lee Batlevi
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Haematologica 101:968-75. 2016
    ..Future studies are warranted to identify predictive biomarkers for treatment response and to develop mechanism-based combination strategies. (clinicaltrials.gov identifier: 00866333). ..
  42. pmc Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF-κB-Controlled Oxidative Stress Responses
    Yusuke Shono
    Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, New York
    Cancer Res 76:377-89. 2016
    ..Taken together, our results provide mechanistic insight and preclinical proof of concept for IT-901 as a novel therapeutic agent to treat human lymphoid tumors and ameliorate graft-versus-host disease...
  43. pmc Novel immunotherapies in lymphoid malignancies
    Connie Lee Batlevi
    Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 330, New York, NY 10065, USA
    Nat Rev Clin Oncol 13:25-40. 2016
    ..We also discuss future strategies to improve these immunotherapies through enhanced engineering, biomarker selection, and mechanism-based combination regimens. ..
  44. ncbi request reprint Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma
    Georgios V Georgakis
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 132:503-11. 2006
    ..Our data suggest that PTEN phosphorylation and activation of CD30, CD40 and RANK may play a role in activating Akt in HRS cells...
  45. ncbi request reprint Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy
    Gregory M Chronowski
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 55:36-43. 2003
    ..Cardiac toxicity and second malignancies, particularly the incidence of solid tumors in terms of the RT field size treated, were also examined...